Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07483073 · ClinicalTrials.gov registry record · Phase 2
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07483073 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 60 participants.
The verdict
NCT07483073, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.
Interventions
- DRUG Mirikizumab - Intravenous (IV)
- DRUG Mirikizumab - Subcutaneous (SC)
- DRUG LY4395089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-05-04 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07483073
The ClinicalTrials.gov registry entry for NCT07483073 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Mirikizumab - Intravenous (IV) is the first listed.
NCT07483073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07483073 about?
NCT07483073 is a clinical study titled "A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease". Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adul...
What is the current status of trial NCT07483073?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-05-04. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07483073?
The interventions under investigation include: Mirikizumab - Intravenous (IV) (DRUG), Mirikizumab - Subcutaneous (SC) (DRUG), LY4395089 (DRUG).
Who is sponsoring clinical trial NCT07483073?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.